> There's a metric crap ton of money going into the research of new antibiotics It's getting more attention, but its been faltering for a long time. https://n

> There's a metric crap ton of money going into the research of new antibiotics It's getting more attention, but its been faltering for a long time. https://news.bloomberglaw.com/health-law-and-business/antibiotic-research-lacks-funds-in-fight-against-resistant-germs https://news.bloomberglaw.com/health-law-and-business/antibi... > Venture capitalists are investing far less funds to develop new antibiotics than they are for oncology drugs, according to a new report that highlights the need for more financial incentives to fight off the growing threat of drug-resistant bacteria. > The report, published Monday by the Biotechnology Innovation Organization, found that investors are increasingly shying away from antibiotic research due in part to large companies exiting the space. That’s left small companies, that typically rely on investment capital, struggling to carry out new clinical trials. > Newer antibiotics are more important than ever as the Covid-19 pandemic has forced people into hospitals for longer periods of time, increasing the chances for the spread of antibiotic-resistant germs, the biotech trade group said. > But in the past 10 years, venture capital funding for U.S. antibiotic development amounted to $1.6 billion, compared to $26.5 billion for oncology, according to Monday’s report. The group noted that there are currently 64 new antibacterial therapeutics in the clinical trial pipeline, 80% of which originated from small companies. The report mentioned is The State of Innovation in Antibacterial Therapeutics - https://www.bio.org/sites/default/files/2022-04/BIO-Antibacterial-Report-2022.pdf https://www.bio.org/sites/default/files/2022-04/BIO-Antibact...